Full Press Release Details
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer.
GLUE
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Key Takeaway: Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Price reaction · baseline $9.44 (2024-12-10 close) · hit after-hours · 1 other GLUE headline(s) in the window, move may be shared
day 0 close
-9.9%
day 1
-17.5%
day 3 · peak
-18.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+67%
120-day peak, hindsight
Typical move
13.3%
average across 9 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
MRT-2359
Phase 2 · Castration-Resistant Prostate Cancer (CRPC)